Company · Private
Life Biosciences
Advancing partial reprogramming toward the clinic with an initial focus on optic neuropathy.
EvidenceEarly
Listing
Private
Ticker
—
Headquarters
Boston, US
Founded
2017
Technology
Partial epigenetic reprogramming (OSK)
Category
Market cap
Private
Longevity thesis
Starting in the eye contains delivery and safety risk while still testing the core rejuvenation hypothesis in humans.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| ER-100 | IND-enabling | NAION / glaucoma |
Recent developments
- 30 Jul 2026Non-human primate vision restoration data supported IND filing.
Scientific evidence
EvidenceEarly
Primate data; first-in-human not yet dosed.
LONGEFI analysis
The clearest near-term test of whether reprogramming can be given to a human safely. Field-defining regardless of outcome.
Analysis is research commentary. It is not investment advice or a recommendation.